Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

María Reig

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
United European Gastroenterology Journal|July 6, 2021
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugsÁlvaro Díaz-González, Víctor Sapena, Loreto Boix, et al.
World Journal of Hepatology|September 26, 2022
Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenibVíctor Sapena, Massimo Iavarone, Loreto Boix, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2025
Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomesMarta Fortuny, Marta García-Calonge, Óscar Arrabal, et al.
Hepatology (Baltimore, Md.)|September 13, 2017
Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse eventsJordi Rimola, Álvaro Díaz-González, Anna Darnell, et al.
Cells|September 9, 2022
miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular CarcinomaPatricia de la Cruz-Ojeda, Tobias Schmid, Loreto Boix, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 6, 2020
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trialsÁlvaro Díaz-González, Víctor Sapena, Loreto Boix, et al.
Journal of Patient-Reported Outcomes|April 8, 2025
Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trialManuel De la Torre-Aláez, Ana Matilla, María Varela, et al.
Medicina Clinica|January 19, 2021
Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETHMaría Reig, Alejandro Forner, Matías A Ávila, et al.
BMC Gastroenterology|February 3, 2025
Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer riskNúria Granel, Gemma Iserte, Concepció Bartres, et al.
Medicina Clinica|March 11, 2017
Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centersCarlos Rodríguez de Lope, María Reig, Ana Matilla, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
United European Gastroenterology Journal|July 6, 2021
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugsÁlvaro Díaz-González, Víctor Sapena, Loreto Boix, et al.
World Journal of Hepatology|September 26, 2022
Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenibVíctor Sapena, Massimo Iavarone, Loreto Boix, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2025
Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomesMarta Fortuny, Marta García-Calonge, Óscar Arrabal, et al.
Hepatology (Baltimore, Md.)|September 13, 2017
Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse eventsJordi Rimola, Álvaro Díaz-González, Anna Darnell, et al.
Cells|September 9, 2022
miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular CarcinomaPatricia de la Cruz-Ojeda, Tobias Schmid, Loreto Boix, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 6, 2020
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trialsÁlvaro Díaz-González, Víctor Sapena, Loreto Boix, et al.
Journal of Patient-Reported Outcomes|April 8, 2025
Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trialManuel De la Torre-Aláez, Ana Matilla, María Varela, et al.
Medicina Clinica|January 19, 2021
Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETHMaría Reig, Alejandro Forner, Matías A Ávila, et al.
BMC Gastroenterology|February 3, 2025
Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer riskNúria Granel, Gemma Iserte, Concepció Bartres, et al.
Medicina Clinica|March 11, 2017
Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centersCarlos Rodríguez de Lope, María Reig, Ana Matilla, et al.
Pageof 7